

**Northern, Eastern & Western Devon Clinical Commissioning Group**  
**South Devon and Torbay Clinical Commissioning Group**

Notes of the meeting of the South and West Devon Formulary Interface Group

Tuesday 14<sup>th</sup> March 2014, 2pm – 4.30pm

The Watermark, Erme Court, Leonards Road, Ivybridge PL21 0SZ

<b>Present:</b>	Chris Roome (CR) – Head of Clinical Effectiveness	NEW Devon CCG
	Phil Melliush (PM) – GP– Chair	South Devon & Torbay CCG
	Bill Nolan (BN) – GP	South Devon & Torbay CCG
	Larissa Sullivan (LS) – Interface Pharmacist	NEW Devon CCG
	Gareth Franklin (GF) – Clinical Guidance Manager	NEW Devon CCG
	Iain Roberts (IR) – Lead MO Pharmacist	South Devon & Torbay CCG
	Carol Webb (CW) – Joint Formularies Technician	NEW Devon CCG
	Margaret Hinchliffe (MH)	Lay member
	Paul Manson (PLM) – Lead MO Pharmacist	NEW Devon CCG
	Andrew Gunatilleke (AG1) – Consultant, Chair SDNT DTC	South Devon NHS Trust
	Elena Mercer (EM) – Formulary Pharmacist	NEW Devon CCG
	Keith Gillespie (KG) - GP	NEW Devon CCG
	David Gwynne - GP	NEW Devon CCG
	Jeremy Morris (JM) – Formulary Pharmacist	Plymouth Hospitals NHS Trust
	Emma Hewitt (EH) – Joint Formulary Pharmacist	NEW Devon CCG
<b>Apologies</b>	Steve Cooke (SC) – Chief Pharmacist	Plymouth Community Healthcare
	Paul Humphriss (PH) - Head of Medicines Management	Torbay and Southern Devon Health and Care NHS Trust

**1 Welcome:** Introductions were made and apologies as noted above.

**3 Notes of last meeting 14<sup>th</sup> February 2013:** These were noted and agreed.

**Action log:**

- **Revised Osteoporosis guidance:** Specialists across Devon have produced a first draft of the revised osteoporosis guidance, to be brought to a future meeting.
- **Cardiology:** LMWH, although there is further work to be done on the possibility of extending the current South Devon guidance it was agreed for the merged guidance to go ahead, highlighting the differences in the Western Locality and the South Devon CCG area.
- **Epilepsy:** Rebecca Bell has drafted an interpretation on the recent MHRA information on brand name prescribing, it was noted again that this issue is very complex.

**Action: Draft to be brought to the April meeting**

- **Chapter 7 Obstetrics, gynaecology and urinary tract disorders**
  - Primary care use of econazole is very low. It was decided not to include this in the merged formulary
  - Carbetocin is not used Derriford
  - Bladder instillation products used in Derriford have been checked
  - Route to progress solifenacin/trospium application, this is to be discussed at a formulary meeting. Appropriate information is being gathered using a short check list

**Northern, Eastern & Western Devon Clinical Commissioning Group**  
**South Devon and Torbay Clinical Commissioning Group**

- **Chapter 3 Respiratory**

- Theophylline 60mg/5mL is used in Derriford so will be included in the formulary
- Shared care: CR reported that there has been agreement between the LMC and the CCG and a framework developed of the shared care that will be funded across the whole of Devon, starting in April.

**4 Chapter 12 ENT**

The merge of this chapter was completed by Carol Webb Comments and decisions:

- Ichthamol & glycerine ear drops – not to be included in the merged formulary
- Anti-infective preparations for otitis externa were discussed and it was agreed that the products additional to the primary care guidelines were appropriate. Other comments:
  - Gentamicin drops – to be listed as amber, specialist use. Gentamicin HC to remain blue
  - Sofradex drops – the ‘colour’ of these was discussed in the light of the second-line us in the North and East Devon Formulary. It was agreed that they should remain as red, hospital only, and that they are not recommended for primary care use be re-enforced
- Cocaine nasal products, the 25% nasal paste is no longer used in Derriford so this will be removed from the formulary. The 10% nasal spray is still used in Torbay Hospital; this will remain in the formulary and clearly marked for use in Torbay only
- Nasal spray information, the brief notes were agreed to be added. These notes come from a current nasal spray leaflet, patient information leaflets produced by the Medicines Optimisation Teams will be hosted now in the CCG websites and the formulary will link to these as appropriate
- Glyceryl and glucose nasal spray will not be included as this is no longer used
- Sterimar, there was discussion about including this as a product to be prescribed. It was agreed to include as a blue, second line treatment
- Sympathomimetic topical nasal decongestants, there was discussion about these and it was agreed to include xylometazoline as blue. It was proposed not to include ephedrine if it is no longer used in Derriford. To include as red, hospital only, if it is used.  
**Action: To ascertain use of ephedrine in Derriford**
- Benzocaine and codeine mouthwash, this is only used in Derriford so will be noted as such
- Mouthwash solution tablets (thymol), these are used in hospital so it was agreed to include these as hospital only

**5 Chapter 13 Skin**

The PAJF had very recently been reviewed; a complete review of the SDJF chapter had not been done for some time. The merged chapter therefore includes many items not currently in the SDJF. It was agreed to accept the merged chapter and for a review of this chapter to be conducted. GF and CW are meeting with Dr Ng in Torbay Hospital on the 20<sup>th</sup> March.

Comments and decisions:

- The comment was made about including doxycycline in the Rosacea guidance, it was

**Northern, Eastern & Western Devon Clinical Commissioning Group**  
**South Devon and Torbay Clinical Commissioning Group**

	<p>agreed to leave this for the review of the chapter</p> <ul style="list-style-type: none"> <li>• Fucidin H, Fucibet are to be included as they are included in the primary care antibacterial guidelines</li> <li>• It was agreed to not include minocycline as a treatment options for acne</li> <li>• Eflornithine, this is only included in one of the current four Devon formularies. It was agreed not to include this in the merged formulary</li> </ul>
<b>7</b>	<p><b>Recent drug decisions including NICE</b></p> <p>These were noted</p>
<b>8</b>	<p><b>MHRA Drug Safety Update – February</b></p> <p>These were noted.</p> <p>Combined hormonal contraceptives and VTE risk, it was noted that the perception is that the guidance is not that different to the current. It was noted that the colours in the SDJF reflected the risk. It was agreed to add a short statement and a link to the Drug Safety Update.</p>
	<p><b>Any other business</b></p> <ul style="list-style-type: none"> <li>• There had been discussion at the last formulary meeting about the launch date for the new South and West Formulary. This was discussed again and a date of the 1<sup>st</sup> June was noted.</li> <li>• Apologies for the April meeting: MH, PM, EM and AG will be delayed.</li> </ul>
<p><b>Next meeting:</b> Friday 11<sup>th</sup> April 2014 2pm – 4:30pm The Watermark, Ivybridge PL21 0SZ</p>	

South and West Devon Formulary Group – Action log			
Date	Action	Responsible	Completed
June 2013	To bring a revised osteoporosis pathway to future meeting	GF	
Sept 2013	An update on the dressings project to be given to the meeting after the next dressings meeting	TM	
Dec 13	<p><b>Brand names for epilepsy treatments</b></p> <ul style="list-style-type: none"> <li>• To brief the committee on this when available</li> </ul>	IR	
Feb 14	To add guidance on medication reviews in the elderly to an agenda when available	AG	
Mar 14	<p><b>Chapter 12 ENT</b></p> <ul style="list-style-type: none"> <li>• To ascertain use of ephedrine in Derriford</li> </ul>	JM	